Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genital Herpesvirus
BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; a Vaccine Candidate for Genital Herpes
September 2nd, 2008
BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted BioVex's Clinical Trial Application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEX HSV2. ImmunoVEX HSV2 is a novel live-attenuated vaccine which has been rationally designed to remove the genes that allow herpes virus to avoid the immune system. This should allow the immune system to recognize and mount a powerful immune response against the causative agent of...
Source: Cancer Weekly (2008-09-02)
|
